The Chemerin/ChemR23 Axis Plays a Pivotal Role in the Pathogenesis of Intestinal Damage in a Murine Model of Graft Versus Host Disease

Blood ◽  
2015 ◽  
Vol 126 (23) ◽  
pp. 3077-3077 ◽  
Author(s):  
Paola Vinci ◽  
Camilla Recordati ◽  
Donatella Bardelli ◽  
Claudia Cappuzzello ◽  
Valeria Fumagalli ◽  
...  

Abstract Allogeneic haematopoietic-stem-cell transplantation (HSCT) is the treatment of choice for many malignant and non-malignant disorders. However, Graft-versus -Host Disease (GvHD), the major complication of allogeneic HSCT, limits its wider application. Among different sites that can be involved, gastrointestinal GvHD represents the major cause of patients morbidity and mortality. The infiltration of different cell subsets into target organs is an important step in GvHD pathogenesis, and the modulation of cell trafficking could represent a promising strategy for GvHD prophylaxis and treatment. Chemerin has been recently identified as a chemotactic protein, which is produced by several tissues during inflammation and binds the G protein-coupled receptor ChemR23, expressed by immature myeloid and plasmacytoid Dendritic Cells, macrophages and natural killer cells. The aim of this study was to evaluate the potential role of Chemerin/ChemR23 axis in the pathogenesis of GvHD, in order to identify disease-specific pathways exploitable for developing new potential therapeutic targets. For this purpose, lethally irradiated Balb/C recipient mice were transplanted with bone marrow cells and splenocytes obtained from ChemR23deficient (ChemR23-/-) C57BL6 mice. After transplantation, mice were monitored daily for survival and GvHD severity. Recipient mice were sacrificed at different time points to evaluate Chemerin production and leukocytes infiltration in skin, lung, liver, and gut by using different techniques, such as ELISA, histopathology, FACS and PCR. Starting from day +6 after transplantation, Chemerin plasma levels appeared significantly higher in both wild type (WT) and ChemR23-/- mice who developed GvHD (WT mean level=86.8 ng/ml; range=80.1-91.9; ChemR23-/- mean level=83.8 ng/ml; range=70.5-103.6, n=6, day+7) compared to syngeneic controls (mean level=62.8 ng/ml; range=49.2-82.5, n=6, day+7), p=0.02. Interestingly, ChemR23-/- mice developed a more severe GvHD compared to mice transplanted with WT cells. In particular, ChemR23-/- transplantedmice showed a higher mortality rate (at day +28 after HSCT: 85% mortality in ChemR23-/- vs 25% in WT, p=0.0004, n=45) (Fig. 1). Differences in GvHD score between ChemR23-/- and WT transplanted mice resulted by a significantly increase in weight loss, associated to severe diarrhea. In accordance, histopathologic analysis performed on GvHD target organs showed a significantly higher GvHD score in large intestine of ChemR23-/- transplanted mice, whereas no differences were found in other GvHD target organs. In addition, a deeper histological analysis on large intestine showed that tissue damage is characterized by crypt hyperplasia and atrophy, epithelium apoptosis and colitis. Moreover, FACS analysis of large intestine infiltrating leukocytes showed an higher neutrophils frequency in ChemR23-/- transplantedmice compared to WT (neutrophils=10.39%, range 6.5%-15.1% versus neutrophils=5.84%, range 2.6%-12.8%, respectively, p=0.001, n=10). This observation was also obtained by analyzing the mesenteric lymphnode. The higher neutrophils infiltration was also confirmed by immunohistochemistry evaluating the number of myeloperoxidase (MPO) positive cells and by quantitative PCR detecting MPO expression (ChemR23-/- mean 2-ΔΔCt =22.35, range 2.43-46.05; WT mean 2-ΔΔCt =6.42, range 0.20-19.23; p=0.04, n=8). All these findings suggest that the Chemerin/ChemR23 axis play a crucial role in intestinal GVHD. Further studies are needed to better understand the mechanisms underling the severe damage observed in the gastrointestinal tract of mice transplanted with ChemR23-/- cells. Figure 1. Figure 1. Disclosures No relevant conflicts of interest to declare.

Blood ◽  
2020 ◽  
Vol 136 (Supplement 1) ◽  
pp. 4-4
Author(s):  
Huihui Liu ◽  
Zhengyu Yu ◽  
Bo Tang ◽  
Shengchao Miao ◽  
Chenchen Qin ◽  
...  

Acute graft-versus-host disease (aGVHD) is a lethal complication after allogeneic hematopoietic stem cell transplantation (allo-HSCT). As a complex immunopathology, aGVHD depends on the recognition of host antigens by donor T cells and induces augmented response of alloreactive T cells. Despite considerable achievements in the treatment of aGVHD, it remains a major clinical problem for the patients undergoing allo-HSCT. Therefore, it is necessary to further illustrate new mechanisms and develop novel therapeutic strategies of aGVHD. Previously we reported LYG1 (Lysozyme G-like 1) as a novel classical secretory protein promoted antitumor function of T cell. In this study, the role of LYG1 in aGVHD was investigated. Firstly, we examined whether LYG1 affected the alloreactivity of CD4+ T cells in vitro by MLR assay and discovered that LYG1 deficiency reduced the activation of CD4+ T cells and Th1 ratio, but increased Treg ratio. Then we confirmed these observations using a major MHC mismatched aGVHD model by transferring T cells sorting from WT B6 or Lyg1-/- mice with bone marrow cells from WT B6 mice into lethally irradiated BALB/c mice. The alloreactive CD4+ T cells and the proportions of Th1 cells decreased whereas the proportions of Treg cells increased in spleens and livers in mice receiving Lyg1-/- T cells. LYG1-deficient T cells attenuated aGVHD severity, inhibited the expression of CXCL9 and CXCL10 and restrained CD4+ T cells infiltrating in livers. Furthermore, administration of recombinant LYG1 protein intraperitoneally aggravated aGVHD by promoting IFN-γ production. More importantly, LYG1 deficiency did not affect GVT (graft-versus-tumor) effects. In summary, we demonstrate LYG1 regulates aGVHD via modulating the alloreactivity of CD4+ T cells and differentiation of Th1/Treg cells. Our study indicates that LYG1 may be a novel target in aGVHD by mitigating aGVHD without impairing GVT function. The therapeutic effect of targeting LYG1 is required in future investigations. Funding This study was supported by grant from The National Natural Science Foundation of China (NSFC) (Grant Number 81600144) and grant from Research Foundation of Peking University First Hospital. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2018 ◽  
Vol 132 (Supplement 1) ◽  
pp. 5680-5680 ◽  
Author(s):  
Chen Xiaomei ◽  
Jianyu Weng ◽  
Peilong Lai ◽  
Xin Huang ◽  
Wang Yulian ◽  
...  

Abstract To investigate the effects of Artesunate treatment on chronic graft-versus-host disease (cGVHD). Recipient BALB/cJ mice received 8 × 106 bone marrow cells with 8 × 106 spleen cells from B10.D2 mice. Artesunate solubilized in acetone was injected intraperitoneally every day at the dose of 1 mg/kg at Day 28 after transplatation. The clinical scores, survival times and histopathological damage were analyzed. The frequency of Th17 and Tregs in PB and spleens from the mice was evaluated by flow cytometry. In addition, we cultured the CD4+ T cells from the spleens of mice in vitro, and stimulated these cells with artesunate, the frequency of Th17 and Tregs in these splenocytes was evaluated by flow cytometry. Artesunate administration diminishes clinical and histopathological damage and improved the survival of cGVHD mice. Artesunate contributed to Tregs development (4.45±0.04 vs 8.40±0.23; 6.62±0.24 vs 10.48±0.48; p<0.05) while decreased Th17 cells (4.45±0.04 vs 8.40±0.23; 6.62±0.24 vs 10.48±0.48; p<0.05)expressions both in PB and spleens, and decreased the Th17/Treg ratio (0.34±0.05 vs 0.09±0.03; 0.19±0.03 vs 0.06+0.02; P<0.01. Moreover, artesunate suppressed the Th17 cells expressions (0.82±0.37% vs 3.39±1.22% p<0.01) and contributed to Tregs development (34.63±1.29% vs 14.28±1.69% p<0.001), and also decreased the Th17/Treg ratio 0.24±0.09vs 0.02±0.01; p<0.05) in vitro. Artesunate suppressed the Th17 cells expressions and contributed to Tregs development. These studies provide nowsights into the artemisinin and identify artesunate as a novel drug for cGVHD. Disclosures No relevant conflicts of interest to declare.


Blood ◽  
2009 ◽  
Vol 114 (22) ◽  
pp. 4487-4487
Author(s):  
Hisakazu Nishimori ◽  
Haruko Sugiyama ◽  
Koichiro Kobayashi ◽  
Yoshiko Yamasuji ◽  
Eisei Kondo ◽  
...  

Abstract Abstract 4487 Chronic graft-versus-host disease (cGVHD) remains a major cause of late death and morbidity after allogeneic hematopoietic cell transplantation, and the treatment of cGVHD remains challenging. All-trans retinoic acid (ATRA), a potent vitamin A derivative, can regulate immune responses. Synthetic retinoid Am80, which shows biological activity approximately 10 times more potent than that of ATRA by binding to RARα and RARβ, but not RARγ, also reduces the severity and progression of immune disease models, including those for contact dermatitis, collagen-induced arthritis, allergic encephalomyelitis, and atherosclerosis. We hypothesized that the administration of ATRA or Am80 could modulate cGVHD. BALB/c (H-2d) mice were subjected to sublethal irradiation and injected with 8 × 106 T-cell-depleted bone marrow cells and 8 × 106 spleen cells from major histocompatibility complex-matched, multiple minor histocompatibility antigen-mismatched B10.D2 (H-2d) mice. Then, the mice were given oral ATRA (200 μg/body), Am80 (1.0 mg/kg body weight), or vehicle daily, beginning from day 0. ATRA slightly decreased the clinical cGVHD score, whereas Am80 significantly reduced the score (Table). When administered daily, Am80 decreased the clinical score beginning from day 21, as in a treatment setting (data not shown). Histopathological examination of the skin showed significantly reduced GVHD pathology in recipients of Am80 (Table). Flow cytometry analysis of the peripheral draining lymph nodes on day 16 showed significant reductions in IFN-γ+, IL-17+, and Foxp3+ cells in Am80-treated recipients compared to controls (Table), whereas no reduction in IL-13+ cells was observed. Cytometric bead arrays and enzyme-linked immunosorbent assays (ELISA) revealed decreased levels of the cytokines IFN-γ, IL-17, TNF-α, and IL-6 in the supernatant of peripheral lymph nodes from Am80-administered recipients (data not shown). Real-time RT-PCR of ears from these recipients on day 21 showed that the administration of Am80 reduced the expression of Foxp3 and TGF-β (Table and data not shown). Therefore, the administration of retinoids ameliorates cGVHD by reducing Th1 and Th17 inflammatory cytokines and the fibrosis factor TGF-β. Thus, treatment with retinoids may be effective for prophylaxis and treatment of cGVHD. Disclosures: No relevant conflicts of interest to declare.


2021 ◽  
Vol 21 (1) ◽  
Author(s):  
Hideto Ikarashi ◽  
Naohiko Aketa ◽  
Eisuke Shimizu ◽  
Yoji Takano ◽  
Tetsuya Kawakita ◽  
...  

Abstract Background Chronic ocular graft-versus-host disease (oGVHD) is an ocular comorbidity of graft-versus-host disease (GVHD) that usually occurs concurrently with systemic manifestations. Failure to detect and treat oGVHD in its early stages may lead to progression of ocular signs and symptoms leading to oGVHD that is refractory to conventional treatment. Case presentation We report the clinical course of a 19-year-old male and a 59-year-old female with severe and progressive chronic oGVHD without concurrent systemic signs of chronic graft-versus-host disease (cGVHD). Although their systemic conditions had been stable, both suffered from severe oGVHD and were referred to our clinic. Both cases exhibited marked improvement in conjunctival inflammation and fibrotic changes after amniotic membrane transplantation (AMT). Both cases underwent keratoplasty eventually to stabilize ocular surface conditions and to improve visual function. Conclusions We reported the clinical outcomes of 2 cases of chronic oGVHD without concurrent systemic comorbidities that were treated with AMT. The clinician should be aware that cGVHD may persist in target organs even in the absence of concurrent systemic comorbidities following seemingly successful systemic treatment. A multidisciplinary team approach is essential in the early detection and therapeutic intervention for chronic oGVHD.


Molecules ◽  
2021 ◽  
Vol 26 (14) ◽  
pp. 4237
Author(s):  
Abdellatif Bouazzaoui ◽  
Ahmed A. H. Abdellatif ◽  
Faisal A. Al-Allaf ◽  
Neda M. Bogari ◽  
Mohiuddin M. Taher ◽  
...  

Systemic steroids are used to treat acute graft-versus-host disease (aGVHD) caused by allogenic bone marrow transplantation (allo-BMT); however, their prolonged use results in complications. Hence, new agents for treating aGVHD are required. Recently, a new compound A (CpdA), with anti-inflammatory activity and reduced side effects compared to steroids, has been identified. Here, we aimed to determine whether CpdA can improve the outcome of aGVHD when administered after transplantation in a mouse model (C57BL/6 in B6D2F1). After conditioning with 9Gy total body irradiation, mice were infused with bone marrow (BM) cells and splenocytes from either syngeneic (B6D2F1) or allogeneic (C57BL/6) donors. The animals were subsequently treated (3 days/week) with 7.5 mg/kg CpdA from day +15 to day +28; the controls received 0.9% NaCl. Thereafter, the incidence and severity of aGVHD in aGVHD target organs were analyzed. Survival and clinical scores did not differ significantly; however, CpdA-treated animals showed high cell infiltration in the target organs. In bulk mixed lymphocyte reactions, CpdA treatment reduced the cell proliferation and expression of inflammatory cytokines and chemokines compared to controls, whereas levels of TNF, IL-23, chemokines, and chemokine receptors increased. CpdA significantly reduced proliferation in vitro but increased T cell infiltration in target organs.


2005 ◽  
Vol 360 (1461) ◽  
pp. 1747-1767 ◽  
Author(s):  
Bruce R Blazar ◽  
William J Murphy

Haematopoietic stem cell transplantation (HSCT) offers promise for the treatment of haematological and immune disorders, solid tumours, and as a tolerance inducing regimen for organ transplantation. Allogeneic HSCTs engraftment requires immunosuppression and the anti-tumour effects are dependent upon the immune effector cells that are contained within or generated from the donor graft. However, significant toxicities currently limit its efficacy. These problems include: (i) graft-versus-host disease (GVHD) in which donor T cells attack the recipient resulting in multi-organ attack and morbidity, (ii) a profound period of immune deficiency following HSCT, and (iii) donor graft rejection. Currently available methods to prevent or treat GVHD with systemic immunosuppression can lead to impaired immune recovery, increased opportunistic infections, and higher relapse rates. This review will provide an overview of GVHD pathophysiology and discuss the roles of various cells, pathways, and factors in the GVHD generation process and in the preservation of graft-versus-tumour effects. Variables that need to be taken into consideration in attempting to extrapolate preclinical results to the clinical paradigm will be highlighted.


Biologia ◽  
2020 ◽  
Vol 75 (11) ◽  
pp. 2045-2052
Author(s):  
Ivana Shawkatová ◽  
Eva Bojtárová ◽  
Monika Kováčová ◽  
Kristína Klučková ◽  
Mária Kušíková ◽  
...  

Sign in / Sign up

Export Citation Format

Share Document